ATC categoryNon steroidal antiinflammatory drugs
ATC subcategoryOther combined anti-flu agents
Generic nameParacetamol, Chlorpheniramine maleate, Phenylephrine hydrochloride
Each tablet contains:
active ingredients: acetaminophen (paracetamol)-325 mg, chlorpheniramine maleate-2 mg, phenylephrine hydrochloride-5 mg;
excipients: microcrystalline cellulose, lactose monohydrate, povidone, magnesium stearate.
4′-Hydroxyacetanilide; 4-acetamidophenol; 103-90-2
(1R)-1-(3-Hydroxyphenyl)-2-(methylamino)ethanol hydrochloride; 61-76-7
(3RS)-3-(4-Chlorophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine hydrogen (Z)-butenedioate; 113-92-8
Analgesic, antipyretic, histamine H1-receptor antagonist, sympathomimetic; R05X.
Acetaminophen is a clinically proven analgesic-antipyretic. Acetaminophen produces analgesia by elevation of the pain threshold and antipyresis through action on the hypothalamic heat-regulating center. Acetaminophen is equal to aspirin in analgesic and antipyretic effectiveness and it is unlikely to produce many of the side effects associated with aspirin and aspirin-containing products.
Phenylephrine is a decongestant. It constricts blood vessels. This reduces the blood flow to certain areas, which decreases swelling and allows nasal and respiratory passages to open up.
Chlorpheniramine maleate is an antihistamine that provides temporary relief of runny nose, sneezing and watery and itchy eyes.
Anti-Cold is used to treat nasal congestion; itchy, watery eyes; itchy throat; sneezing; headache; fever; and other symptoms associated with allergies, hay fever, and the common cold. Anti-Cold may also be used for purposes other than those listed in this medication guide.
Relieving symptoms of colds, hay fever, and allergies such as headache, sinus pain, nasal and sinus congestion, sneezing, watery eyes, runny nose, fever, and itching of the nose or throat. It may also be used for other conditions as determined by doctor.
Take each dose with a full glass of water.
Administration of Anti-Cold tablets in children 2-6 years of age should be directed by a physician.
In children 6-12 years of age the usual dose is 1 tablet every 4-6 hours.
In adults and children elder 12 years of age the usual dose is 2 tablets every 4-6 hours.
Do not take more than 4 doses a day. Never take more of this medication than is directed. The maximum amount of acetaminophen for adults is 1 gram (about 3 Anti-Cold tablets) per dose and 4 grams (about 12 Anti-Cold tablets) per day. Taking more acetaminophen can be damaging to the liver. If you drink more than three alcoholic beverages per day, talk to your doctor before taking acetaminophen and never take more than 2 grams (about 6 Anti-Cold tablets) per day.
If you miss a dose of Anti-Cold tablets and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
This drug is contraindicated for children younger than 2 years of age.
Unless your doctor approves, do not use these products if:
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:- Dizziness; drowsiness; dry mouth, nose, or throat; headache; nausea; nervousness; trouble sleeping.
Seek medical attention right away if any of these SEVERE side effects occur:
Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
What happens if you overdose?
It is unknown if Anti-Cold tablets can cause harm to the fetus. If you become pregnant while taking Anti-Cold tablets, discuss with your doctor the benefits and risks of using Anti-Cold tablets during pregnancy.
Some of the ingredients in Anti-Cold tablets are excreted in breast milk. If you are or will be breast-feeding while you are using Anti-Cold tablets, check with your doctor or pharmacist to discuss the risks to your baby.
Paracetamol is the principal para-aminophenol derivative in use. Paracetamol has analgesic and antipyretic properties and weak anti-inflammatory activity. The mechanism of analgesic action remains to be fully elucidated, but may be due to inhibition of prostaglandin synthesis both centrally and peripherally. Paracetamol is used for the relief of mild to moderate pain and minor febrile conditions.
Paracetamol is readily absorbed from the gastrointestinal tract with peak plasma concentrations occurring about 10 to 60 minutes after oral administration. Paracetamol is distributed into most body tissues. It crosses the placenta and is present in breast milk. Plasma-protein binding is negligible at usual therapeutic concentrations but increases with increasing concentrations. The elimination half-life of Paracetamol varies from about 1 to 3 hours.
Paracetamol is metabolized predominantly in the liver and excreted in the urine mainly as the glucuronide and sulfate conjugates. Less than 5% is excreted as unchanged paracetamol. A minor hydroxylated metabolite (n-acetyl-p-benzoquinoneimine), which is usually produced in very small amounts by mixed-function oxidases in the liver and kidney and which is usually detoxified by conjugation with glutathione, may accumulate following Paracetamol overdosage and cause tissue damage.
Paracetamol, a para-aminophenol derivative, has analgesic and antipyretic properties and weak anti-inflammatory activity. Paracetamol is given by mouth for mild to moderate pain and for fever. Paracetamol is often the analgesic or antipyretic of choice especially in patients in whom salicylates or other NSAIDs are contra-indicated. Such patients include asthmatics or those with a history of peptic ulcer, or children. Its use is also generally preferred in elderly patients.
The usual dose by mouth is 0.5 to 1 g every 4 to 6 hours up to a maximum of 4 g daily. Usual doses in children are: under 3 months, 10 mg per kg body-weight (reduced to 5 mg per kg if jaundiced); 3 months to 1 year, 60 to 120 mg; 1 to 5 years, 120 to 250 mg; 6 to 12 years, 250 to 500 mg. These doses may be given every 4 to 6 hours when necessary up to a maximum of 4 doses in 24 hours.
Side effects of Paracetamol are rare and usually mild, although haematological reactions including thrombocytopenia, leucopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. Skin rashes, and other hypersensitivity reactions occur occasionally.
Overdosage with Paracetamol can result in severe liver damage and sometimes, acute renal tubular necrosis. Prompt treatment with acetylcysteine or methionine is essential.
Acute overdosage with Paracetamol, whether accidental or deliberate, is relatively common and can be extremely serious because of the narrow margin between therapeutic and toxic doses. Ingestions of as 10 to 15 g of Paracetamol by adults may cause sever hepatocellular necrosis and, less often, renal tubular necrosis. Indeed, any patient should be considered at risk of severe liver damage if they have ingested more than 150 mg per kg body-weight of Paracetamol or 12 g or more in total, whichever is the smaller.
Early features of overdosage such as nausea and vomiting usually settle within 24 hours; other early symptoms may include lethargy and sweating. Abdominal pain may be the first indication of liver damage, which is not usually apparent for 24 to 48 hours and sometimes may be delayed for up to 4 to 6 days after ingestion. Liver damage is generally at a maximum 72 to 96 hours after ingestion. Hepatic failure, encephalopathy, coma, and death may result. Complications of hepatic failure include acidosis, cerebral oedema, haemorrhage, hypoglycaemia, hypotension, infection, and renal failure. An increasing prothrombin time is a reliable indicator of deteriorating liver function and it is recommended by some that the prothrombin time should be measured regularly. Measurement of serum concentrations of aspartate aminotransferase and alanine aminotransferase is also considered to be of value. Patients receiving enzyme-inducing drugs or those with a history of alcohol abuse are at special risk of hepatic damage, as may be patients suffering from malnutrition such as those with anorexia or AIDS. It has also been suggested that fasting may predispose to hepatotoxicity.
Toxicity following overdosage with Paracetamol has been attributed to the production of a minor but highly reactive metabolite, N-acetyl-p-benzoquinoneimine (NABQI) by mixed function oxidaze enzymes in the liver and kidney. The amount of NABQI produced after normal doses of Paracetamol is usually completely detoxified by conjugation with glutathione and excreted as mercaptopurine and cysteine conjugates. In Paracetamol overdosage, tissue stores of glutathione become depleted, allowing NABQI to accumulate and bind to sulfhydryl groups within hepatocytes causing cell damage. Substances capable of replenishing depleted stores of glutathione, such as acetylcysteine or methionine, are thus used as antidotes in Paracetamol overdosage. Acetylcysteine may also be involved in the repair of damaged tissue.
Treatment of Paracetamol overdosage: Prompt treatment is essential, even when there are no obvious symptoms, and all patients should be admitted to hospital; full supportive measures should also be instituted. Activated charcoal may be given to reduce gastrointestinal absorption, if it can be given within 1 hour of the overdose, and if more than 150 mg per kg of Paracetamol has been ingested. However, if acetylcysteine or methionine is to be given by mouth the charcoal is best cleared from stomach to prevent it reducing the absorption of antidote.
Choice of antidote: acetylcysteine is most effective when administered during the first 8 hours following ingestion of the overdosage and the effect diminishes progressively thereafter. In the UK, an initial dose of 150 mg per kg body-weight of acetylcysteine in 200 ml of glucose 5% is given intravenously over 15 minutes, followed by an intravenous infusion of 50 mg per kg in 500 ml of glucose 5% over the next 4 hours and then 100 mg per kg in one litre over the next 16 hours. Sodium chloride 0.9% may be used where glucose 5% is unsuitable. The volume of intravenous fluids should be modified for children. In the USA, acetylcysteine is given by mouth in an initial dose of 140 mg per kg as a 5% solution followed by 70 mg per kg every 4 hours for an additional 17 doses.
Methionine is an alternative to acetylcysteine and, likewise, is most effective when given as early as possible following Paracetamol overdosage. The usual dose to methionine is 2.5 g by mouth every 4 hours for 4 doses starting less than 10 to 12 hours after ingestion of the paracetamol and provided the patient is not vomiting.
The use of Paracetamol should be avoided in all trimesters of pregnancy.
Since it is not known if Paracetamol is distributed into milk, the drug should be used with caution in nursing women.
Paracetamol should be given with care to patients with impaired kidney or liver function. It should also be given with care to patients with alcohol dependence.
The risk of Paracetamol toxicity may be increased in patients receiving other potentially drugs or drugs that induce liver microsomal enzymes. The absorption of Paracetamol may be accelerated by drugs such as metoclopramide. Excretion may be affected and plasma concentrations altered when administered with probenecid. Colestyramine reduces the absorption of paracetamol if given within one hour of Paracetamol administration.
Chlorpheniramine maleate, an alkylamine derivative, is a sedating antihistamine that causes a moderate degree of sedation; it also has antimuscarinic activity. Chlorpheniramine maleate diminishes or abolishes the major actions of histamine in the body by competitive, reversible blockade of histamine H1-receptor sites on tissues; it does not inactivate histamine or prevent its synthesis, nor, in most cases, its release. Histamine H1 receptors are responsible for vasodilation, increased capillary permeability, flare and itch reactions in the skin, and to some extent for contraction of smooth muscle in the bronchi and gastrointestinal tract.
Chlorpheniramine is a racemic mixture; the dextrorotatory isomer, dexchlorpheniramine, has approximately twice the activity of Chlorpheniramine by weight.
Chlorpheniramine maleate is absorbed relatively slowly from the gastrointestinal tract, peak plasma concentrations occurring about 2.5 to 6 hours after administration by mouth. Bioavailability is low, values of 25 to 50% having been reported. Chlorpheniramine appears to undergo considerable first-pass metabolism. About 70% of Chlorpheniramine in the circulation is bound to plasma proteins. There is wide inter-individual variation in the pharmacokinetics of Chlorpheniramine; values ranging from 2 to 43 hours have been reported for the half-life. Chlorpheniramine is widely distributed in the body, including passage into the CNS.
Chlorpheniramine maleate is extensively metabolized. Metabolites include desmethyl- and didesmethylchlorpheniramine. Unchanged drug and metabolites are excreted primarily in the urine; excretion is dependent on urinary pH and flow rate: Only trace amounts have been found in the faeces.
A duration of action of 4 to 6 hours has been reported; this is shorter than may be predicted from pharmacokinetic parameters.
More rapid and extensive absorption, faster clearance, and a shorter half-life have been reported in children.
Chlorpheniramine maleate is used for symptomatic relief of allergic conditions including urticaria and angioedema, rhinitis, and conjunctivitis, and in pruritic skin disorders. It is common ingredient of compound preparations for symptomatic treatment of coughs and common cold.
Chlorpheniramine maleate is given by mouth in doses of 4 mg every 4 to 6 hours up to a maximum of 24 mg daily. Doses for children are: 1 to 2 years, 1 mg twice daily; 2 to 5 years, 1 mg every 4 to 6 hours (maximum 6 mg daily); 6 to 12 years, 2 mg every 4 to 6 hours (maximum 12 mg daily).
Overdosage with sedating antihistamines is associated with antimuscarinic, extrapyramidal, and CNS effects. When CNS stimulation predominates over CNS depression, which is more likely in children or the elderly, it causes ataxia, excitement, tremors, psychoses, hallucinations, and convulsions; hyperpyrexia may also occur. Deepening coma and cardiorespiratory collapse may follow. In adults, CNS depression is more common with drowsiness, coma, and convulsions, progressing to respiratory failure and cardiovascular collapse.
Treatment of overdosage: treatment is symptomatic and supportive.
Phenylephrine has low oral bioavailability owing to irregular absorption and first-pass metabolism by monoamine oxidase in the gut and liver. When injected subcutaneously or intramuscularly it takes 10 to 15 minutes to act; subcutaneous and intramuscular injections are effective for up to about 1 hour and up to about 2 hours, respectively. Intravenous injections are effective for about 20 minutes.
Systemic absorption follows topical application.
As for Sympathomimetics; phenylephrine has mainly alpha-agonist effects. It has a longer duration of action than noradrenaline and an excessive vasopressor response may cause a prolonged rise in blood pressure. It induces tachycardia or reflex bradycardia and should therefore be avoided in severe hyperthyroidism and used with caution in severe ischaemic heart disease.
Since phenylephrine is absorbed through the mucosa systemic effects may follow application to the eyes or the nasal mucosa. In particular, phenylephrine 10% eye drops should be avoided or only used with extreme caution in infants and the elderly since they can have powerful systemic effects.
Use of phenylephrine in the eye may liberate pigment granules from the iris, especially when given in high doses to elderly patients. Ophthalmic solutions of phenylephrine are contra-indicated in patients with angle-closure glaucoma. Corneal clouding may occur if corneal epithelium has been denuded or damaged.
Excessive or prolonged use of phenylephrine nasal drops can lead to rebound congestion.
Phenylephrine hydrochloride is irritant and may cause local discomfort at the site of application; extravasation of the injection may even cause local tissue necrosis.
Treatment of Adverse Effects:
As for Sympathomimetics.
Interactions with sympathomimetics are complex and may be hazardous; they result mainly from their pharmacological actions at alpha and beta receptors.
To be dispensed withоut prescription.
Round with a flat surface white tablets, odorless, scored on one side and beveled on both sides.
2 blister packets with 10 tablets in each with leaflet inserted in the cardboard box.
Store at a room temperature (15-250C), in a dry place, out of the reach of children. Protect from light.